Abstracts tagged "B cells"

Abstract Number: 1080 • 2016 ACR/ARHP Annual Meeting
B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes
Annie Visser¹, Marieke E. Doorenspleet², Niek de Vries³, Fred K.L. Spijkervet⁴, Arjan Vissink⁵, Hendrika Bootsma⁶, Frans G.M. Kroese¹ and Nicolaas A Bos¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lacrimal glands. Patients with pSS have increased clonal…
Abstract Number: 2089 • 2016 ACR/ARHP Annual Meeting
Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome
Ryo Hisada¹, Masaru Kato¹, Hisako Nakagawa², Eri Sugawara¹, Masatoshi Kanda¹, Kazumasa Ohmura¹, Ikuma Nakagawa¹, Kenji Oku¹, Toshiyuki Bohgaki¹, Olga Amengual¹, Tetsuya Horita¹, Shinsuke Yasuda¹ and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Probiotics Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Antiphospholipid syndrome (APS) is a well-characterized autoimmune and thrombotic disorder but its pathogenesis remains to be elucidated. Genomic studies have revealed the association of signal…
Abstract Number: 2878 • 2016 ACR/ARHP Annual Meeting
Major Lymphocyte Populations Share a Common Interferon Signature but Express Cell Type-Specific Interferon Pathway Genes in SLE
Mikhail Olferiev¹, Kyriakos A. Kirou², David Fernandez³, Khalili Leila¹, Dina Greenman¹ and Mary K. Crow⁴, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁴Department of Medicine, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY
Background/Purpose: All lymphocyte populations contribute to SLE pathogenesis, but little is known of the specific gene transcripts particularly involved in each cell type. Activation of…
Abstract Number: 4L • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Epratuzumab in Patients with Moderate-to-Severe Systemic Lupus Erythematosus: Results from Two Phase 3 Randomized, Placebo-Controlled Trials
Megan E. B. Clowse¹, Daniel J Wallace², Richard Furie³, Michelle Petri⁴, Marilyn Pike⁵, Piotr Leszczynski⁶, C Michael Neuwelt⁷, Kathryn Hobbs⁸, Mauro Keiserman⁹, Liliana Duca¹⁰, Kenneth Kalunian¹¹, Sabine Bongardt¹², Christian Stach¹², Carolyn Beaudot¹³, Brian Kilgallen¹³, Catrinel Galateanu¹⁴ and Caroline Gordon^15,16, ¹Rheumatology, Duke University, Durham, NC, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³North Shore LIJ Health System, Manhasset, NY, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Med Pharm Consulting Inc, Cambridge, MA, ⁶Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁷Division of Rheumatology, Alameda County Medical Center, Oakland, CA, ⁸Denver Arthritis Clinic, Denver, CO, ⁹School of Medicine, Pontifical Catholic University, Porto Alegre, Brazil, ¹⁰Clinica Neomed, Brasov, Romania, ¹¹UCSD School of Medicine, La Jolla, CA, ¹²UCB Pharma, Monheim, Germany, ¹³UCB Pharma, Raleigh, NC, ¹⁴UCB Pharma, Brussels, Belgium, ¹⁵Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ¹⁶NIHR/Wellcome Trust Clinical Research Facility, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: In phase 2b trials, epratuzumab, a humanized anti-CD22 mAb that modulates B cell signaling without total B cell depletion, significantly improved disease activity in…
Abstract Number: 1 • 2015 ACR/ARHP Annual Meeting
The Integrin Very Late Antigen-4 Plays a Key Role in the Recruitment of B Cells at the Inflammatory Foci
Estefanía Armas-González¹, Ana Díaz-Martín², María Jesús Domínguez-Luis³, María Teresa Arce-Franco² and Federico Díaz-González⁴, ¹Universidad de La Laguna, Pharmacology Department, Tenerife, Spain, ²Hospital Universitario de Canarias, Rheumatology Service, Tenerife, Spain, ³CIBICAN, Center of Biomedical Research of the Canary Islands, University of La Laguna, Tenerife, Spain, ⁴Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain
Background/Purpose: Experimental data suggest that B cells must migrate and accumulate into the synovial membrane to exert their pathogenic role in rheumatoid arthritis (RA). Leukocyte…
Abstract Number: 1108 • 2015 ACR/ARHP Annual Meeting
Epratuzumab, a Monoclonal Antibody Targeting CD22 on B Cells, Stimulates the Phosphorylation of Upstream Inhibitory Signals of the B Cell Receptor
Simon Lumb¹, Sarah J. Fleischer², Capucine Daridon², Alison Maloney¹, Anthony Shock¹ and Thomas Dorner², ¹UCB Pharma, Slough, United Kingdom, ²Charité University Medicine Berlin, CC12, Dept. Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Center Berlin (DRFZ), a Leibniz Institute, Berlin, Germany
Background/Purpose: Epratuzumab, a humanized monoclonal antibody targeting CD22, is currently in phase 3 clinical trials in patients with systemic lupus erythematosus (SLE). Previous work suggests…
Abstract Number: 1822 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics of the Selective B-Cell Lymphoma-2 (Bcl-2) Inhibitor, ABT-199, in Female Subjects with Systemic Lupus Erythromatosus
Mukul Minocha¹, Shekman Wong², Jiewei Zeng², Peng Lu³, Jeroen Medema² and Ahmed Othman⁴, ¹Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Worcester, MA, ⁴AbbVie, North Chicago, IL
Background/Purpose: Selective Inhibition of Bcl-2 pathway may offer clinical efficacy in Systemic Lupus Erythromatosus (SLE) by restoring apoptosis in autoreactive cells, which may lead to…
Abstract Number: 502 • 2015 ACR/ARHP Annual Meeting
Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Jennifer Barnard¹, Nida Meednu², Kelly Callahan¹, Karen Boyle³, Lynette Keyes-Elstein³, Beverly Welch⁴, Ellen Goldmuntz⁵ and Jennifer H. Anolik¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Rho Federal Systems, Inc., Chapel Hill, NC, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵DAIT, NIAID/NIH, Bethesda, MD
Background/Purpose: TNF is a key pro-inflammatory cytokine in normal immune responses and pathologically in the rheumatoid arthritis (RA) synovium, thus representing a key treatment target…
Abstract Number: 1110 • 2015 ACR/ARHP Annual Meeting
A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Charlotte Hua¹, Rachel Audo², Nataliya Yeremenko³, Dominique Baeten⁴, Michael Hahne², Bernard Combe⁵, Jacques Morel⁵ and Claire I. Daien⁵, ¹Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²IGMM-CNRS UMR5535, Montpellier, France, ³Academic medical center, University of Amsterdam, Amsterdam, France, ⁴1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: B cells may have a negative regulatory role, mainly mediated by interleukin 10 (IL-10). We recently showed that regulatory B-cell functions are impaired in…
Abstract Number: 1848 • 2015 ACR/ARHP Annual Meeting
Increased Expression of Bruton Tyrosine Kinase in Patients with Lupus Nephritis and Its Clinic Significance
Wei Kong, Wei Deng, Xuebing Feng, Genhong Yao, Weiwei Chen, Xiaojun Tang, Yue Sun, Saisai Huang, Zhuoya Zhang, Bingyu Shi and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multiorgan impairment including glomerulonephritis, cutaneous lesions and arthritis. B cells participate in the onset…
Abstract Number: 602 • 2015 ACR/ARHP Annual Meeting
Efficacy of Very Low Dose (100mg) Rituximab in Active Rheumatoid Arthritis Despite Combination DMARD-Single Center, Prospective, Observational Study
Padmanabha Shenoy¹ and Manish Bavaliya², ¹Dept. of rheumatology and clinical immunology, Amrita Institute of medical science and research institute, Kochi, India, ²Department of rheumatology and clinical immunology, Amrita institute of medical sciences and research institute, Kochi, India
Background/Purpose: Rituximab is an anti-CD20 antibody that represents a therapeutic alternative for the patients with rheumatoid arthritis. It has been proven that rituximab at a…
Abstract Number: 1113 • 2015 ACR/ARHP Annual Meeting
B Cell Signature Profiling in Systemic Lupus Erythematosus Patients on Belimumab
Michelle T. Ngo¹, Abigail Benitez², Kimberly J. Payne², Michael De Vera³, Terry Ann Milford² and Karina Marianne D. Torralba⁴, ¹Rheumatology, Loma Linda University, Loma Linda, CA, ²Loma Linda University, Loma Linda, CA, ³Transplant Surgery, Loma Linda University, Loma Linda, CA, ⁴Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA
Background/Purpose: The B cell pool is composed of subsets with different phenotypes and functions that mainly have effector functions to maintain immunologic tolerance. These…
Abstract Number: 1853 • 2015 ACR/ARHP Annual Meeting
Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Asiya Chida¹, Kevin Cashman¹, Scott Jenks², Louise Hartson¹, Youliang Wang¹, Quan-Zhen Li Li^3,4, Chandra Mohan⁵ and Ignacio Sanz^6,7, ¹Medicine, Emory University, Atlanta, GA, ²Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Immunology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Biomedical Engineering, University of Houston, Houston, TX, ⁶Rheumatology, Emory University, Atlanta, GA, ⁷Medicine/Rheumatology, Emory University, Atlanta, GA
Background/Purpose: IgG antibodies expressing the idiotope for the 9G4 idiotype, the framework-1 hydrophobic patch (HP) of VH4-34, are expanded in SLE and provide a unique…
Abstract Number: 729 • 2015 ACR/ARHP Annual Meeting
The Effect of Belimumab on Peripheral Blood Cells in Patients with Systemic Lupus Erythematosus
Cosmin Dascalu¹, Anne Davidson², Meggan C. Mackay³, Richard Furie⁴, Weiqing Huang⁵ and Cynthia Aranow⁶, ¹Medicine/Rheumatology, North Shore- Long Island Jewish, Manhasset, NY, ²Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ³Autoimmune & Musculoskeletal Disorders, The Feinstein Institute for Medical Research, Manhasset, NY, ⁴Division of Rheumatology, North Shore LIJ Health System, Lake Success, NY, ⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ⁶Feinstein Institute for Medical Research, Mahasset, NY
Background/Purpose: The anti-BAFF antibody belimumab is the first biologic drug approved for treatment of mild-moderate SLE. While the efficacy of belimumab for this indication is…
Abstract Number: 1114 • 2015 ACR/ARHP Annual Meeting
Profiling Circulating Plasmablasts from Anti-Ro Positive Mothers of Children with Congenital Heart Block to Identify Antigenic Targets Conferring Pathogenicity
Sarah Kongpachith¹, WH Robinson¹, Sara Rasmussen², Robert Clancy³ and Jill P. Buyon³, ¹Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Neonatal lupus (NL) is an uncommon autoimmune disease classically manifest as permanent complete heart block and/or transient cutaneous lesions. By definition of NL, there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].